DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Phase 2

Completed

Conditions: Melanoma
Neoplasm Metastasis

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 141

Registration Number: NCT00001705

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Familial Prostate Cancer

Completed

Conditions: Neoplastic Syndromes, Hereditary
Prostatic Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT00001377

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Phase I Study of Intrathecal Topotecan

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Meningeal Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001333

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

Phase 1

Completed

Conditions: Melanoma
Sarcoma

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001577

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

Phase 1

Completed

Conditions: Sarcoma
Glioma

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001573

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas

Phase 2

Completed

Conditions: Pancreatic Cancer
Pancreatic Neoplasm

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00005926

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Prevention of Osteoporosis in Men With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer
Osteoporosis
Hypogonadism

First Posted Date: 2002-11-13

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 112

Registration Number: NCT00048841

Locations: 🇺🇸
Osteoporosis Prevention & Treatment Center, Pittsburgh, Pennsylvania, United States

Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2002-11-11

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT00048880

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms
Metastases, Neoplasm

First Posted Date: 2002-11-11

Last Posted Date: 2012-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00048893

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Depsipeptide to Treat Thyroid and Other Advanced Cancers

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2002-10-30

Last Posted Date: 2019-12-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00048334

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy